An AI-powered Virtual Reality Brief Intervention for Hospitalized Patients With Alcohol-Associated Liver Disease (SOBER-VR) (SOBER-VR)

November 11, 2026 updated by: Yee Hui Yeo, The Cleveland Clinic

SOBER-VR: An AI-powered Virtual Reality Brief Intervention for Hospitalized Patients With Alcohol-Associated Liver Disease

Alcohol-associated liver disease (ALD) is a leading cause of preventable liver-related morbidity and mortality, with hospitalizations for ALD increasing significantly in recent years. Many patients with ALD and active alcohol use disorder (AUD) are discharged from the hospital without receiving evidence-based behavioral interventions, despite hospitalization representing a teachable moment when patients may be more motivated to change. Psychosocial support in this setting is often limited by short inpatient stays, provider shortages, and workflow barriers. Novel digital health approaches are needed to increase access to structured, personalized behavioral support during hospitalization.

This project aims to assess the feasibility, usability, and clinical relevance of SOBER-VR, a virtual reality (VR) and artificial intelligence (AI)-powered digital therapeutic that delivers motivational interviewing (MI) to hospitalized patients with ALD and active alcohol use. SOBER-VR uses immersive VR to enhance emotional salience and a large language model (LLM)-driven conversational agent to simulate reflective, MI-consistent interactions. The intervention is brief (10-15 minutes), self-guided, and delivered using sanitized, standalone VR headsets with real-time support from trained staff.

Using the NIH ORBIT Model for behavioral intervention development, this Phase Ib single-arm feasibility study will recruit 30 hospitalized patients with ALD and active alcohol use. Participants will use SOBER-VR during their inpatient stay and complete structured assessments post-discharge. The study will evaluate feasibility (recruitment, engagement, and retention), acceptability, usability, and safety of SOBER-VR. Preliminary signals of clinical impact, such as readiness to change, attitude to AUD treatment, among others, will also be explored.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18+ years of age
  • Patients with lived experience of inpatient admissions due to ALD OR a Cleveland Clinic nurse (with experience in healthcare quality)
  • English-speaking

Exclusion Criteria:

  • Unwilling and/or unable to participate
  • Non-English speakers
  • Delirium/acute encephalopathy prevents safe participation
  • Self-reported history of acute and/or severe motion sickness
  • The presence of a facial/head deformity that will prohibit the wearing of a VR HMD
  • Legally blind or deaf
  • Having had a seizure in the past year
  • Those who are pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Device Feasibility
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SOBER-VR cue exposure therapy feasibility

Patient and nurse participants will complete four bi-weekly (twice a month) co-design sessions over two months. Sessions will involve hands-on testing with SOBER-VR to gather feedback on user interface, hardware ergonomics, and comfort.

A virtual reality (VR) and artificial intelligence (AI)-powered digital therapeutic that delivers motivational interviewing (MI) to hospitalized patients with ALD and active alcohol use. SOBER-VR uses immersive VR to enhance emotional salience and a large language model (LLM)-driven conversational agent to simulate reflective, MI-consistent interactions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SOBER-VR Intervention Feasibility, calculated by eligibility yield, consent rate, intervention uptake, and follow-up completion percentages
Time Frame: Week 8

We will consider the study feasible if: >60% of eligible patients consent, >80% of randomized participants complete ≥1 session, and >70% complete follow-up interviews before discharge.

Week 8
System Usability Scale (SUS) of SOBER-VR
Time Frame: Week 8

Usability. System Usability Scale, ranging from 0 to 100 (score ≥70 will indicate acceptable usability) and a structured interview, which explores overall satisfaction, comfort with the VR experience, and perceived relevance of the content.

Week 8
SOBER-VR Acceptability through qualitative satisfaction ratings
Time Frame: Week 8

Measured via structured discharge interviews and satisfaction ratings, focusing on perceptions of SOBER-VR's clarity and overall experience.

Week 8
Incidence of Adverse Events
Time Frame: Week 8

Safety of the SOBER-VR intervention will be assessed by incidence of adverse events, including cybersickness, emotional distress, etc.

Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

July 1, 2027

Study Registration Dates

First Submitted

October 8, 2026

First Submitted That Met QC Criteria

October 8, 2026

First Posted (Actual)

October 15, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 26-503
  • K23AA033142-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.